Download CHRISTUS Schumpert Cancer Treatment Center

CHRISTUS Schumpert Cancer Treatment Center Clinical Trials Available
Breast Cancer: S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Patients with Early-­‐Stage Breast Cancer Receiving Hormone Therapy Study Criteria: • Stage I-­‐III • Postmenopausal Women on one of the following Aromatase Inhibitors (AI): Anastrozole (Arimidex®) 1 mg daily Letrozole (Femara®) 2.5 mg daily Exemestane (Aromasin®) 25 mg daily • Reported 4 out of 10 pain that began or has increased after starting AI therapy -­‐ Pain not related to fracture/traumatic injury or arthritic disease For more information: http://clinicaltrials.gov/ct2/show/NCT01598298?term=NCT01598298&rank=1
S1207: Hormone Therapy With or Without Everolimus in Treating Patients with Stage I-­‐III High-­‐Risk Breast Cancer - Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. - Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. Patients must be high risk by belonging to one of the following risk groups: • Completion of adjuvant chemotherapy and pathologically negative axillary nodes, and a tumor measuring ≥ 2 cm in greatest diameter, and an Oncotype DX® recurrence score (RS) > 25 (completed as standard of care) • Completion of adjuvant chemotherapy, and pathologically 1-­‐3 positive axillary lymph nodes, and an Oncotype DX® RS > 25 • Completion of adjuvant chemotherapy and pathologically 4 or more positive axillary lymph nodes independent of the Oncotype DX® RS in the primary tumor • Completion of neoadjuvant chemotherapy and 4 or more positive nodes pathologically determined prior to or after chemotherapy For More Information:
http://clinicaltrials.gov/ct2/show/NCT01674140?term=NCT01674140&rank=1 CML
CAMN107A 107A: Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment after Achieving and Sustaining MR4.5 (ENESTgoal) Purpose: To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in
patients who achieve MR4.5
Inclusion Criteria:
• Diagnosis of CML
• Treated with at least 1 year of imatinib
• Bcr-Abl level by PCR must be less than or equal to 0.1% and greater than 0.0032%
Exclusion Criteria:
• T315I mutation
• Prior imatinib failure or had accelerated phase or blast crisis CML
• Impaired cardiac function
• Pregnant or lactating women
Other protocol-defined inclusion/exclusion criteria may apply
For More Information:
http://clinicaltrials.gov/ct2/show/record/NCT01744665?term=NCT01744665&rank=1
Renal Cell
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib -
Study Patient Inclusion Criteria: advanced and/or metastatic clear cell or predominantly clear cell RCC Treatment with pazopanib (Votrient) Observation only: Non-­‐interventional, no drug will be provided. No study visits or procedures are mandated per protocol. For More Information:
http://clinicaltrials.gov/ct2/show/NCT01649778?term=NCT01649778&rank=1 For your convenience, the Patient Library, located in the Cancer Treatment Center, is available for computer and internet access to online resources and information. For More Information on Clinical Trials at CHRISTUS Schumpert Cancer Treatment Center Please Contact: Jennifer Powell, RN Research Coordinator Oncology Research (318) 681-­‐6007 [email protected] For More Information on Clinical Trials: http://www.nih.gov/health/clinicaltrials/ http://cancer.gov/clinicaltrials/learningabout www.cancer.org www.clinicaltrials.gov